Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q2- Text added to 2019 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
administered, agonism, airway, biomarker, Blair, Cancer, cell, cohort, discontinue, efficacy, elevated, emax, endpoint, eosinophilic, evidenced, fluctuation, GMP, heavily, Immunotherapy, inflammation, issuer, larger, lt, microenvironment, minimal, PIPE, placement, population, potent, powered, primary, randomized, resale, SITC, statistical, statistically, suggesting, volume, William, wound, York
Removed:
exhaled, Genentech, localized, marker, medical, member, nitric, oxide, Roche, Tecentriq, tolerability
Valuein 2019 Q2 filing- Value in 2019 Q3 filing
Original filings
Filing view